SCHEMBL2368375

SCHEMBL2368375

c1ccc(-c2csc3ncnc(NCC4CC4)c23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.65
MAPK1 P28482 3/20 0.65
HTT P42858 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
ALDH1A1 P00352 3/20 0.65
TNF P01375 1/20 0.62
NOD1 Q9Y239 1/20 0.62
NCOA1 Q15788 1/20 0.58
NCOA3 Q9Y6Q9 1/20 0.58
ADRB3 P13945 1/20 0.58
CCNC P24863 1/20 0.57
CDK8 P49336 1/20 0.57
FGFR1 P11362 5/20 0.55
KDM4E B2RXH2 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
DAPK3 O43293 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
NTRK1 P04629 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369025 0.94 LMNA (0.61) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL23598887 0.86 ADRB3 (0.55) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL31336989 0.85 ADRB3 (0.57) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL3388458 0.84 LMNA (0.64) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL2368726 0.83 HTT (0.66) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL3385124 0.83 SMN1; SMN2 (0.62) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL2369277 0.81 CCNC (0.78) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL2368258 0.81 LMNA (0.55) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL3169227 0.80 MAPK1 (0.65) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL5789044 0.79 ATM (0.65) LMNAMAPK1HTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885MAPK1 667/4885HTT 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.